Intelsius introduces revisions to PharmaTherm line of solutions

NewsGuard 100/100 Score

Intelsius, a DGP company, a designer, manufacturer and distributor of temperature-controlled packaging solutions, introduced revisions to its PharmaTherm™ line of solutions to pharmaceutical industry professionals today at the 13th Annual Cool Chain Europe Summit in Luxembourg. 

"Intelsius is refining one of our best-selling product lines to stay ahead of the constantly changing pharmaceutical industry," said David Walsh, CEO, Intelsius.  "All three new sizes provide optimal thermal protection for pharmaceutical products."  PharmaTherm R solutions are regulatory compliant to meet the qualifications in the new GDP Guidelines for the EU that expanded and became more uniformly regulated in September 2013.  

PharmaTherm R solutions are pre-qualified to the Intelsius High Performance profile and maintain payload integrity during shipments for 72 hours. The three sizes available today utilize the same size coolant across the range and have a universal pack out making them easy to assemble, operationally friendly, tamper-evident and economical to ship. 

"These additions allow more flexibility in payload sizes making them an Intelsius innovation," said Steve Healy, Intelsius global director of sales.  With interchangeable components and common features across the range, suitable solutions are available for all temperature controlled shipping requirements.  The PharmaTherm family now offers pre-qualified 72 hour 2-8 degrees C, 96 hour 15-25 degrees C, PCM and dry ice solutions.

"The revised PharmaTherm line of products will help our customers save on storage space and shipping costs," said Walsh.  "As we continue to protect life's most precious cargo we create innovative products that provide intelligent solutions." PharmaTherm products maintain appropriate temperatures and keep products safe while being transported.  In addition, its discreet design keeps the contents confidential. 

Intelsius serves a wide range of organizations including government agencies, leading pharmaceutical, biopharmaceutical and clinical research industries to major laboratories.  Intelsius is the preferred response partner for human and veterinary epidemic and pandemic events in the UK and the Republic of Ireland.

Source: Intelsius

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals